Prostate cancer biomarkers: from early diagnosis to precision treatment.

Autor: Dahiya V; Amity Institute of Biotechnology, Amity University Haryana, Gurgaon, India, 122413., Hans S; Amity Institute of Biotechnology, Amity University Haryana, Gurgaon, India, 122413., Kumari R; Amity Institute of Biotechnology, Amity University Haryana, Gurgaon, India, 122413., Bagchi G; Amity Institute of Biotechnology, Amity University Haryana, Gurgaon, India, 122413. gbagchi@ggn.amity.edu.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Oct; Vol. 26 (10), pp. 2444-2456. Date of Electronic Publication: 2024 May 14.
DOI: 10.1007/s12094-024-03508-2
Abstrakt: Prostate cancer (PCa) is the second most prevalent cancer in men. In 2020, approximately 1,414,259 new cases were reported that accounted for 3,75,324 deaths (Sung et al. in CA 71:209-249, 2021). PCa is often asymptomatic at early stages; hence, routine screening and monitoring based on reliable biomarkers is crucial for early detection and assessment of cancer progression. Early diagnosis of disease is key step in reducing PCa-induced mortality. Biomarkers such as PSA have played vital role in reducing recent PCa deaths. Recent research has identified many other biomarkers and also refined PSA-based tests for non-invasive diagnosis of PCa in patients. Despite progress in screening methods, an important issue that influences treatment is heterogeneity of the cancer in different individuals, necessitating personalized treatment. Currently, focus is to identify biomarkers that can accurately diagnose PCa at early stage, indicate the stage of the disease, metastatic nature and chances of survival based on individual patient profile (Fig. 1). Fig. 1 Graphical abstract.
(© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).)
Databáze: MEDLINE
Externí odkaz: